BeiGene, a US-based biotechnology company, built a new manufacturing campus and clinical research and development (R&D) centre in Hopewell, New Jersey. The facility offers state-of-the-art US biologic pharmaceutical manufacturing at the commercial stage, along with advanced capabilities for late-stage research and clinical development of innovative cancer medications. BeiGene invested approximately $800m in the project.
The development plan for the new facility was announced in August 2021. The ground-breaking ceremony for the facility was held in April 2022. The initial phase of construction of the facility began in 2022 and it was in July 2024.
The facility helps the company expand and diversify its global supply chain of large-molecule products while furthering its plans to enhance the accessibility of treatments to patients worldwide. Location of BeiGene’s new R&D centre BeiGene acquired a 42-acre (16.9ha) site at the Princeton West Innovation Campus from real estate company Lincoln Equities Group in November 2021 for the development of the project.
The site previously hosted a life sciences campus of Bristol-Myers Squibb (BMS). Lincoln Equities Group and HIG Realty Partners purchased the site from BMS in 2020. The Hopewell site was selected due to its central location and proximity to pharmaceutical research, development, and manufacturing expertise.
BeiGene’s new manufacturing and clinical R&D centre details The site houses 400,000ft2 (37,161.2m2) of commercial-stag.